Ara h 2‐specific IgE epitope‐like peptides inhibit the binding of IgE to Ara h 2 and suppress lgE‐dependent effector cell activation
Clinical & Experimental Allergy · 2023
DOI: 10.1111/cea.14314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2023. Verfasst von Peter Korošec und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia. Hauptthemen laut MEDLINE: Food Hypersensitivity, Peanut Hypersensitivity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS.
Abstract (Originalsprache)
Background
Clinical and experimental analyses indicate a pathognomonic role for allergen IgE crosslinking through epitope–paratope interactions as a major initial step in the cascade leading to effector cell activation and clinical manifestations of lgE‐mediated food allergies. We aimed to undertake the initial development and assessment of Ara h 2‐specific IgE epitope‐like peptides that can bind to allergen‐specific IgE paratopes and suppress effector cell activation.
Methods
We performed biopanning, screening, IgE binding, selection and mapping of peptides. We generated synthetic peptides for use in all functional experiments. ImmunoCAP inhibition, basophil and mast cell activation tests, with LAD2 cells, a human mast cell line were performed. Twenty‐six children or young adults who had peanut allergy were studied.
Results
We identified and selected three linear peptides (DHPRFNRDNDVA, DHPRYGP and DHPRFST), and immunoblot analyses revealed binding to lgE from peanut‐allergic individuals. The peptide sequences were aligned to the disordered region corresponding to the loop between helices 2 and 3 of Ara h 2, and conformational mapping showed that the peptides match the surface of Ara h 2 and h 6 but not other peanut allergens. In ImmunoCAP inhibition experiments, the peptides significantly inhibit the binding of IgE to Ara h 2 ( p < .001). In basophil and mast cell activation tests, the peptides significantly suppressed Ara h 2‐induced effector cell activation ( p < .05) and increased the half‐maximal Ara h 2 effective concentration ( p < .05). Binding of the peptides to specific IgEs did not induce activation of basophils or mast cells.
Conclusions
These studies show that the indicated peptides reduce the allergenic activity of Ara h 2 and suppress lgE‐dependent basophil and mast cell activation. These observations may suggest a novel therapeutic strategy for food allergy based on epitope–paratop blocking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- Peptide Allergy Therapeutics, Ljubljana, Slovenia.
- Department of Pediatrics, University Medical Center, Maribor, Slovenia.
ORCID-Profile: Peter Korošec, Mojca Lunder
Förderung
- Javna Agencija za Raziskovalno Dejavnost RS
Zitieren
APA
Korošec, P., Koren, A., Debeljak, J., Zahirović, A., Skerbinjek-Kavalar, M., Berce, V., Dejanović, L., Luzar, J., Štrukelj, B., & Lunder, M. (2023). Ara h 2‐specific IgE epitope‐like peptides inhibit the binding of IgE to Ara h 2 and suppress lgE‐dependent effector cell activation. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14314
Vancouver
Korošec P, Koren A, Debeljak J, Zahirović A, Skerbinjek-Kavalar M, Berce V, et al. Ara h 2‐specific IgE epitope‐like peptides inhibit the binding of IgE to Ara h 2 and suppress lgE‐dependent effector cell activation. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14314
BibTeX
@article{Koroec2023,
author = {Korošec, Peter and Koren, Ana and Debeljak, Jerneja and Zahirović, Abida and Skerbinjek-Kavalar, Maja and Berce, Vojko and Dejanović, Luka and Luzar, Jernej and Štrukelj, Borut and Lunder, Mojca},
title = {Ara h 2‐specific IgE epitope‐like peptides inhibit the binding of IgE to Ara h 2 and suppress lgE‐dependent effector cell activation},
journal = {Clinical & Experimental Allergy},
year = {2023},
doi = {10.1111/cea.14314}
}
EUVIMED